Navigation Links
Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress

New Sustained-Release Analgesic Significantly Reduces Postop Pain, Opioid Use, and Reduces Opioid Related Adverse Events Compared to Gold Standard Pain Medication

PARSIPPANY, N.J., Dec. 6 /PRNewswire/ -- A Phase II dose escalation study of a single intraoperative administration of EXPAREL(TM) (DepoBupivacaine) in patients who underwent total knee arthroplasty, or TKA, showed that the novel, sustained-release analgesic effectively and safely controlled moderate-to-severe postoperative pain for over 72 hours, it was reported today in a poster at the Biennial World Congress of the International College of Surgeons in Vienna, Austria. Commenting on the results, Kenneth W. Bramlett, MD, Orthopedic Department, West Alabama Research in Birmingham, Alabama concluded EXPAREL significantly reduced postoperative pain, decreased the use of opioids (therefore lowering associated side effects), and allowed some patients to avoid the use of opioids altogether.


EXPAREL, a proprietary product from Pacira Pharmaceuticals, Inc., is a novel long-acting, sustained-release formulation of bupivacaine HCL, a local anesthetic widely used for treating postoperative pain.

Dr. Bramlett said, "EXPAREL effectively controlled moderate to severe pain for more than 72 hours, with better relief achieved with higher doses and a dose-dependent effect in both analgesia and reduction in opioid rescue." He pointed out the clinical importance of the study outcomes noting that EXPAREL efficacy was statistically significant against bupivacaine, the gold standard of local anesthetics, rather than simply placebo, concluding, "EXPAREL may provide safe and effective, prolonged pain relief and an opioid-sparing alternative to currently available local analgesics."

Findings as reported in the poster include:

  • Statistically significant reduction in pain versus Bup/epi in patients receiving EXPAREL 450mg at the end of general anesthesia, 5.0 vs. 7.0 pain intensity (P<0.05).
  • Statistically significant reduction in pain at the time of first opioid use in both EXPAREL 300mg and 450mg patient groups versus active control, 6.4 vs. 7.8 pain intensity and 6.1 vs. 7.8 pain intensity respectively (P<0.05).
  • Pain intensity was also lower with EXPAREL than with Bup/epi during activity at all postoperative intervals evaluated.
  • EXPAREL 450mg also significantly decreased the use of opioid rescue medications throughout the entire evaluation period plus postoperative nausea and vomiting occurrence was 40% lower than in the active control group.
    • Approximately 8% of patients in the EXPAREL 450mg group avoided all opioid use versus zero percent (0%) of patients in the active control group.
  • No differences were found in the safety profile of EXPAREL compared with bupivacaine. There were no clinical signs of either cardiac or central nervous system adverse events.

The multi-center, double-blind, randomized Phase II study used a parallel-group, active-control format to evaluate the efficacy and safety of EXPAREL for prolonged postoperative analgesia. Either a single intraoperative administration of EXPAREL or active control was given via local infiltration to 103 adult patients undergoing TKA in 5 centers across the U.S. and Europe.

TKA is the leading orthopedic surgery in the U.S. with approximately 534,000 procedures performed annually according to the National Center for Health Statistics. It is expected that the number of total knee replacement procedures will increase as our population continues to age.

The Potential for EXPAREL

EXPAREL is a novel formulation of bupivacaine designed to provide effective, safe, prolonged (72 hours) postoperative pain relief in a single administration. Currently available local anesthetics typically have short (about 6 to 8 hours) duration of action resulting in limited pain relief in the first few days following surgery when pain is the most intense.

"The results of this study clearly demonstrate the potential of EXPAREL in fulfilling this unmet need," said Ronald Burch, M.D, PhD, Chief Medical Officer, Pacira. "EXPAREL represents an important advance in pain control that allows for extended delivery of bupivacaine, a well-characterized analgesic with a long-established efficacy and safety record. We look forward to sharing the results of multiple phase II and III clinical trials across a broad range of surgical procedures."

EXPAREL, currently in late Phase III clinical development, is being studied in several different types of surgical procedures where postoperative pain management is especially problematic. It is the latest product to benefit from Pacira Pharmaceutical's proprietary sustained-release DepoFoam(R) technology. DepoFoam technology is designed to address the limitations of widely known and used drugs by enhancing their dosing and/or administration profile. It achieves this by encapsulating the drug in multivesicular liposomal particles which then release the drug over a desired period of time without altering the drug molecule. DepoFoam is a proven technology that is already used in two commercially available products in the U.S. and Europe.

About Pacira

Pacira Pharmaceuticals, Inc. is an acute care specialty pharmaceutical company founded in March, 2007 through the acquisition of the former SkyePharma PLC injectable business, for which an experienced management team was assembled to address the needs of the acute care market. The company's most advanced product, EXPAREL(TM) (DepoBupivacaine), a bupivacaine-based product intended to deliver postoperative pain relief by infiltration, is in late Phase III clinical development. Pacira will also study EXPAREL for nerve block, non-surgical pain such as long bone fracture and for intraarticular injection. EXPAREL benefits from the proprietary DepoFoam Technology owned by Pacira. Two other DepoFoam-based products -- DepoDur(R) and DepoCyt/DepoCyte(R) -- are marketed by partners in several global territories. The DepoFoam technology also forms the basis of multiple development projects providing Pacira an opportunity to expand its pipeline. Pacira owns two cGMP production facilities which produce the two approved products, EXPAREL clinical development and all pipeline materials.

Additional information about Pacira is available at

This news release and the anticipated presentation contain forward-looking statements that involve risks and uncertainties, including statements relating to initiation and progress of the Company's clinical trial programs and the preliminary results from the clinical trials. Actual results could differ materially from those projected and the Company cautions readers not to place undue reliance on the forward-looking statements contained in the release and anticipated presentation.

    Pacira Contact:
    Taunia Markvicka
    Vice President, Commercial Development
    973 254 3565

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations
2. Third Pivotal Phase 3 Study for NicOx Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results
3. Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union
4. Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia
5. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
6. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
7. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
8. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
9. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
10. Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized Moderate Complexity by FDA
11. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
Post Your Comments:
(Date:10/13/2015)... , Oct. 13, 2015  A minimally-invasive treatment just ... the United States.  After more than 10 years of ... 9 approved the use of High Intensity Focused Ultrasound ... cells while protecting surrounding tissue and minimizing chances for ... George Suarez , a pioneering Miami ...
(Date:10/13/2015)... , Oct. 13, 2015  ContraVir Pharmaceuticals, ... "Company"), a biopharmaceutical company focused on the development ... the closing of its previously announced underwritten public ... and warrants to purchase up to 3,000,000 shares ... combined price to the public of $3.00. The ...
(Date:10/13/2015)... -- Measurement in accountable care programs is essential for ... gaps in measurement can result in missed opportunities ... new, peer-reviewed study published in The ... measurement gaps for high-priority conditions and identifies ways ... --> "These gaps in measures present ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... Dr. Poneh Ghasri, dentist in West Hollywood ... 2015. The research, which was conducted at the Dental Institute at King's College London ... between stress during pregnancy and future dental health in the child. For years, researchers ...
(Date:10/13/2015)... ... October 13, 2015 , ... Leading ... Singal's newly launched "Publish Academy" training course . Singal's new program, in ... enrollment today, and marketers around the Internet are weighing in with reviews. , ...
(Date:10/13/2015)... ... October 13, 2015 , ... Scientists in Seattle and Vancouver compared the diagnostic ... or without mesothelioma. Surviving Mesothelioma has just posted an article on the new research. ... in Seattle and the University of British Columbia found that certain genetic alterations were ...
(Date:10/13/2015)... ... October 13, 2015 , ... California Southern ... Nursing. Dr. McLeod—who earned her Doctor of Nursing Practice from the renowned Johns ... spanned four decades. , Dr. McLeod’s long and successful nursing practice included a ...
(Date:10/13/2015)... ... October 13, 2015 , ... Breathing ... people do not breathe correctly. According to T’ai Chi (also spelled “Taiji”) and ... to breathe correctly, in concert with the 7,000 year old tradition they teach, ...
Breaking Medicine News(10 mins):